Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146,872 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
Goodman RS, Di Guardo L, Maurichi A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czapla J, Spagnoletti A, Ambrosini M, Livingstone E, Long GV, Sullivan RJ, Carlino MS, Atkinson V, Trojanello C, Ascierto PA, Schadendorf D, Warburton L, Menzies AM, Santinami M, Johnson DB. Goodman RS, et al. Among authors: lee j. Eur J Cancer. 2023 Nov;194:113354. doi: 10.1016/j.ejca.2023.113354. Epub 2023 Sep 22. Eur J Cancer. 2023. PMID: 37827067 Free PMC article.
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.
Lee J, Ahmed T, Maurichi A, Di Guardo L, Stagno AM, Warburton L, Taylor AM, Livingstone E, Rehman S, Khattak A, Kahler KC, Vanella V, Atkinson V, Millward M, Schadendorf D, Johnson DB, Ascierto PA, Hauschild A, Lo SN, Long GV, Menzies AM, Carlino MS. Lee J, et al. Eur J Cancer. 2023 Jan;179:87-97. doi: 10.1016/j.ejca.2022.11.009. Epub 2022 Nov 12. Eur J Cancer. 2023. PMID: 36509002
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
Harvey C, Nahar KJ, McKeown J, Lo SN, Farag S, Yousaf N, Young K, Tas L, Meerveld-Eggink A, Blank C, Thomas A, McQuade J, Schilling B, Johnson DB, Huertas RM, Arance A, Lee J, Zimmer L, Long GV, Carlino MS, Wang Y, Menzies AM. Harvey C, et al. Among authors: lee j. J Immunother Cancer. 2024 Jan 31;12(1):e008232. doi: 10.1136/jitc-2023-008232. J Immunother Cancer. 2024. PMID: 38296594 Free PMC article.
Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach.
Sussman M, Benner J, Mugwagwa T, Lee J, Hung ST, Yang YM, Chen Y. Sussman M, et al. Among authors: lee j. J Mark Access Health Policy. 2024 Nov 12;12(4):326-341. doi: 10.3390/jmahp12040026. eCollection 2024 Dec. J Mark Access Health Policy. 2024. PMID: 39588279 Free PMC article.
Anhedonia in Major Depressive Disorder: Prevalence and Treatment Expectations and Satisfaction with Treatment Goals Among Patients and Physicians in Asia-Pacific.
Herr K, Berk M, Huang WL, Kato T, Lee JG, Ng CG, Wang Z, Webb TD, Kasahara-Kiritani M, Vandervoort LP. Herr K, et al. Among authors: lee jg. Neuropsychiatr Dis Treat. 2024 Nov 19;20:2177-2191. doi: 10.2147/NDT.S487747. eCollection 2024. Neuropsychiatr Dis Treat. 2024. PMID: 39588177 Free PMC article.
Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial.
Shin CM, Choi SC, Cho JW, Kim SY, Lee OJ, Kim DH, Cho YK, Lee JY, Lee SK, Shin JE, Kim GH, Park SY, Hong SJ, Jung HK, Lee SJ, Youn YH, Jeon SW, Sung IK, Park MI, Lee OY. Shin CM, et al. Among authors: lee jy. Neurogastroenterol Motil. 2024 Nov 25:e14969. doi: 10.1111/nmo.14969. Online ahead of print. Neurogastroenterol Motil. 2024. PMID: 39587796
146,872 results
You have reached the last available page of results. Please see the User Guide for more information.